Loading stock data…
$4.62-0.58 (-11.15%)
Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. in the Healthcare sector is trading at $4.62 with a market capitalization of $7M. The stock is currently near its 52-week low of $1.51, remaining 60.8% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.28M↑ | -$12.19M↓ | -$7.04M↓ | -$1.84M↑ | -$2.66M |
| Net Income | -$20.17M↑ | -$35.06M↓ | -$1.16M↑ | -$1.78M↑ | -$2.66M |
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Insc...